HIV /AIDS : RARE PERSONS WHO NEVER SHOWS AIDS SYMPTOMS-LONG TIME NON RESPODERS(LNTPs) HAVING VIRUS & CONTACT WITH POSITIVE-THE REASON-WHY?

PROF.DRRAM ,HIV/AIDS,SEX DISEASES,SEX WEAKNESS & ABORTION SPECIALIST
profdrram@gmail.com,+917838059592,+919832025033 DELHI –NCR,INDIA
FOLLOW ON FACE BOOK:www.facebook.com/drramkumar
FOLLOW ON TWITTER:www.twitter.com/profdrram
Since,the earliest days of the HIV epidemic, scientists have regularly observed HIV-infected individuals who did not progress to AIDS and were able to maintain stable CD4 counts and low-to-undetectable viral loads without treatment,often for decades and even regular contact with hiv partners.These are about one in 500 and these are called LONG TERM NON RESPONDERS OR LNTPs,theirs study of Gene has given chance to produce a medicine called CCR5 inhibitor-class drug, Selzentry (maraviroc).
Stephen Crohn, "The Man Who Can't Catch AIDS"

Stephen Crohn, who was dubbed "The man who can't catch AIDS" by the U.K's Independent newspaper, was found to have had an anomaly called a "delta 32" mutation on CCR5 receptors of his CD4 cells, the mutation of which effectively prevents HIV from entering target immune cells. Crohn first came to the attention of Dr. Bill Paxton of the Aaron Diamond AIDS Research Center in 1996 after tests revealed no signs of infection despite having had multiple sexual partners, all of who died of AIDS. The mutation has since been identified in less than 1% of the population.
These can maintain high CD4/CD8 T cell counts for more than 15 to 20 years without the use of antiretroviral drugs. Within this group is a rarer subset called "elite controllers" who are able to sustain viral loads of less than 50 copies/mL throughout the course of infection. It is estimated that there are 1,500 elite controllers in the U.S.

In studying these groups since the mid-1990s, we have begun identify some of the mechanisms by which viremic control is achieved. Among the discoveries is a genetic mutation in the FUT2 gene, which has been found to occur in 10-20% of Europeans and is believed to confer a protective association against heterosexual HIV infection. The anomaly was first noted in 2000 among a group of female Senegalese sex workers who appeared to have an innate resistance to HIV.
A number of other genetic characteristics have since been identified in LTNPs, including one associated with the production of certain classes of human leukocyte antigens (HLAs), known to exert control over HIV INFECTION.
CCR5-delta-32 mutation :
Timothy Ray Brown, also known as "the Berlin Patient," is the first person believed to have been "functionally cured" of HIV.Born in the U.S., Brown was given a bone marrow transplant in 2009 to treat his acute leukemia. Doctors at Charité Hospital in Berlin, Germany selected a stem cell donor with two copies of the CCR5-delta-32 mutation, known to confer to HIV resistance. Routine tests performed soon after the transplant revealed that the HIV antibodies had decreased to such as to suggest the complete eradication of the virus from his system.
While Brown continues to show no signs of HIV, two subsequent stem cell transplants conducted by doctors at Brigham and Women's Hospital failed to achieve similar results, with both patients experiencing viral rebound after 10 and 13 months of undetectable tests. These patients were not transplanted with the Delta 32 mutation, however.
Donor 45:
In 2010, a gay African American man known simply as "Donor 45" was found to possess a powerful HIV neutralizing antibody called VRC01 by researchers at the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases (NIAID).Subsequent research in 2011 identified two HIV-infected Africans with similar VRC01 antibodies.What was particularly compelling about the discovery was the fact that VRC01 is able to bind to 90% of all global strains of HIV, effectively blocking infection even as the virus mutates. Due the high genetic diversity of HIV, most defensive antibodies are unable to achieve this level of action.
The discovery helped broaden research into the stimulation of broadly neutralizing antibodies, which may one day prevent or slow disease progression without the use of antiretroviral drugs.